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Endovascular treatment of a malignant aortoesophageal
fistula
Robert J. Feezor, MD,a Philip J. Hess, MD,b and W. Anthony Lee, MD,a Gainesville, FLA 48-year-oldman with a recent diagnosis of T4N1M0 small-cell carcinoma
of the esophagus presented with acute onset of hematemesis. An urgent
computed tomography (CT) angiogram was obtained and showed an aorto-
esophageal fistula (AEF) (A, arrow). He was then immediately taken to the
operating room for thoracic endovascular aortic repair (TEVAR) using a
TAG 26 mm  100 mm device (W.L. Gore, Flagstaff, AZ) (B). The final
angiogram showed complete exclusion of the fistula (C). On postoperative
day 1, the patient suffered acute respiratory distress that was attributed to left
bronchial obstruction by the tumor. After selective right mainstem intuba-
tion, a stent (Ultraflex 12 mm 40 mm; Boston Scientific, Natick, MA) was
placed in the left mainstem bronchus (Cover).
The patient was discharged on postoperative day 12. He underwent radiation
therapy and remained symptom-free living at home.A follow-upCT scan2months
afterTEVARshowed the endograft tobe ingoodpositionwithno recurrent fistula.
However, at 3 months he presented with hemoptysis that was bronchoscopically
localized to the left mainstem bronchus. The patient suffered a respiratory arrest
from this recurrent episode, and the family decided to withdraw support.
Primary small-cell carcinoma of the esophagus is an extremely rare but
aggressive malignant tumor that comprises only 1% to 2% of all esophageal
neoplasms. The prognosis is almost uniformly poor, with median survival of less
than 6 months; treatment is mostly palliative.1 One of the most dreaded
complications is tumor invasion into the aorta, causing an AEF. The symptoms
of AEF are classically described as back pain, sentinel hemorrhage, and massive
hematemesis after a symptom-free interval, collectively known as Chiari triad.2
Endovascular treatment of these lesions has been reported as a potential thera-
peutic option. Although this option may offer a more rapid and less morbid
method of stopping the bleeding, the long-term sequelae of an endograft within
an infected intravascular space remain guarded. Topel et al3 reported six cases of
AEF treated with TEVAR; four patients subsequently required aortic replace-
ment with homografts. Of the two patients who did not undergo surgery, both
were dead within 8 weeks of discharge. In conclusion, endovascular repair of
AEFs may offer a temporizing solution as a bridge to later definitive (and more
elective) open surgical aortic replacement, which must be weighed against the
overall prognosis of the underlying malignancy.
REFERENCES
1. Levine MS, Pantongrag-Brown L, Buck JL, Buetow PC, Lowry MA, Sobin LH. Small-cell
carcinoma of the esophagus: radiographic findings. Radiology 1996;199:703-5.
2. Metz R, Kimmings AN, VerhagenHJ, Rinkes IH, vanHillegersberg R. Aortoesophageal fistula
successfully treated by endovascular stent-graft. Ann Thorac Surg 2006;82:1117-9.
3. Topel I, Stehr A, Steinbauer MG, Piso P, Schlitt HJ, Kasprzak PM. Surgical strategy in
aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopre-
served homografts. Ann Surg 2007;246:853-9.
From the Divisions of Vascular Surgery and Endovascular Therapy,a and Thoracic and Cardiovas-
cular Surgery,b Department of Surgery, University of Florida College of Medicine.
Competition of interest: none.
J Vasc Surg 2009;49:778
0741-5214/$36.00
Copyright © 2009 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.05.066
778
